Novel Ellipsoid Chitosan-Phthalate Lecithin Nanoparticles for siRNA Delivery

Saeed, Ramzi Mukred; Abdullah, Mohammad S; Ahram, Mamoun; Taha, Mutasem O.

doi:10.3389/fbioe.2021.695371

Cited by 9 publications

(3 citation statements)

References 80 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the large molecular weight (~14 kDa), abundant negative charge, and poor stability of free siRNA molecules limit their application. 54 , 55 Weng et al coupled nanoscale ZPM with poly(2-diethylamino) ethyl methacrylate (PDEA)-branched polyethyleneimine (bPEI) (PDE). Utilizing the strong binding affinity between bPEI and siRNA, along with the ultra-pH-sensitive nature of PDEA (pKa ≈ 6.4), ZPM@PDE-siZEB1/2 enters cells through endocytosis, undergoes rapid protonation in endosomes/lysosomes (pH 4.5–6.0), which facilitates endosomal escape, and releases siRNA into the cytoplasm.…”

Section: Application Of Nanoparticles In the Treatment Of Alimentioning

confidence: 99%

Novel application of nanomedicine for the treatment of acute lung injury: a literature review

Chen,

Tang

2024

Ther Adv Respir Dis

View full text Add to dashboard Cite

Nanoparticles have attracted extensive attention due to their high degree of cell targeting, biocompatibility, controllable biological activity, and outstanding pharmacokinetics. Changing the size, morphology, and surface chemical groups of nanoparticles can increase the biological distribution of agents to achieve precise tissue targeting and optimize therapeutic effects. Examples of their use include nanoparticles designed for increasing antigen-specific immune responses, developing vaccines, and treating inflammatory diseases. Nanoparticles show the potential to become a new generation of therapeutic agents for regulating inflammation. Recently, many nanomaterials with targeted properties have been developed to treat acute lung injury/acute respiratory distress syndrome (ALI/ARDS). In this review, we provide a brief explanation of the pathological mechanism underlying ALI/ARDS and a systematic overview of the latest technology and research progress in nanomedicine treatments of ALI, including improved nanocarriers, nanozymes, and nanovaccines for the targeted treatment of lung injury. Ultimately, these nanomedicines will be used for the clinical treatment of ALI/ARDS.

show abstract

Section: Application Of Nanoparticles In the Treatment Of Alimentioning

confidence: 99%

Novel application of nanomedicine for the treatment of acute lung injury: a literature review

Chen,

Tang

2024

Ther Adv Respir Dis

View full text Add to dashboard Cite

show abstract

“…Common biodegradable polymers such as poly (lactic acid) (PLA), poly (glycolic acid) (PGA), and poly (lactic-co-glycolide) (PLGA) are already approved by the Food and Drug Administration (FDA) for drug delivery applications. These polymers offer excellent biocompatibility and low immunogenicity ( Wood, 2018 ; Saeed et al, 2021 ). Similar to lipids, surface charges of the resultant nanoparticles and the molecular weight of the constituting polymer influence siRNA delivery to the desired site.…”

Section: Nanoparticles (Nps) Used For the Sirna Therapy Of Covid-19mentioning

confidence: 99%

Potential of siRNA in COVID-19 therapy: Emphasis on in silico design and nanoparticles based delivery

Fopase

Panda

Rajendran

et al. 2023

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Small interfering RNA (siRNA)-mediated mRNA degradation approach have imparted its eminence against several difficult-to-treat genetic disorders and other allied diseases. Viral outbreaks and resulting pandemics have repeatedly threatened public health and questioned human preparedness at the forefront of drug design and biomedical readiness. During the recent pandemic caused by the SARS-CoV-2, mRNA-based vaccination strategies have paved the way for a new era of RNA therapeutics. RNA Interference (RNAi) based approach using small interfering RNA may complement clinical management of the COVID-19. RNA Interference approach will primarily work by restricting the synthesis of the proteins required for viral replication, thereby hampering viral cellular entry and trafficking by targeting host as well as protein factors. Despite promising benefits, the stability of small interfering RNA in the physiological environment is of grave concern as well as site-directed targeted delivery and evasion of the immune system require immediate attention. In this regard, nanotechnology offers viable solutions for these challenges. The review highlights the potential of small interfering RNAs targeted toward specific regions of the viral genome and the features of nanoformulations necessary for the entrapment and delivery of small interfering RNAs. In silico design of small interfering RNA for different variants of SARS-CoV-2 has been discussed. Various nanoparticles as promising carriers of small interfering RNAs along with their salient properties, including surface functionalization, are summarized. This review will help tackle the real-world challenges encountered by the in vivo delivery of small interfering RNAs, ensuring a safe, stable, and readily available drug candidate for efficient management of SARS-CoV-2 in the future.

show abstract

“…For example, inhaled siRNAs can directly target and have long-term contact with pulmonary cells, which can be quickly effective and avoid first-pass elimination ( Merckx et al, 2018 ; Zhu et al, 2022 ). However, large molecular weight (∼14 kDa), abundant negative charge, and poor stability of naked siRNAs limit their permeation across cell membranes ( Wittrup and Lieberman 2015 ; Saeed et al, 2021 ). Thus, the development of new carriers for siRNA delivery into pulmonary cells is urgent.…”

Section: Introductionmentioning

confidence: 99%

Nanoscale Porphyrin Metal-Organic Frameworks Deliver siRNA for Alleviating Early Pulmonary Fibrosis in Acute Lung Injury

Weng

Dongdong

et al. 2022

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Acute lung injury (ALI) has high mortality and still lacks novel and efficient therapies. Zinc finger E-box binding homeobox 1 and 2 (ZEB1/2) are highly expressed in the early stage of ALI and are positively correlated with the progression of pulmonary fibrosis. Herein, we developed a nanoscale Zr(IV)-based porphyrin metal-organic (ZPM) framework to deliver small interfering ZEB1/2 (siZEB1/2) to alleviate early pulmonary fibrosis during ALI. This pH-responsive nano-ZPM system could effectively protect siRNAs during lung delivery until after internalization and rapidly trigger siRNA release under the mildly acidic environment of the endo/lysosome (pH 4.0–6.5) for transfection and gene silencing. Furthermore, the in vivo studies confirmed that this nano-ZPM system could anchor in inflamed lungs. Moreover, the ZEB1/2 silencing led to increased E-cadherin and decreased α-SMA levels. Overall, the nano-ZPM system was an excellent non-viral vector system to deliver siRNAs to alleviate early pulmonary fibrosis during ALI.

show abstract

Novel Ellipsoid Chitosan-Phthalate Lecithin Nanoparticles for siRNA Delivery

Abstract: Graphical Abstract

Cited by 9 publications

References 80 publications

Novel application of nanomedicine for the treatment of acute lung injury: a literature review

Novel application of nanomedicine for the treatment of acute lung injury: a literature review

Potential of siRNA in COVID-19 therapy: Emphasis on in silico design and nanoparticles based delivery

Nanoscale Porphyrin Metal-Organic Frameworks Deliver siRNA for Alleviating Early Pulmonary Fibrosis in Acute Lung Injury

Contact Info

Product

Resources

About